CXL is a technique that uses ultraviolent A (UV-A) light and riboflavin to increase the biomechanical rigidity of the cornea and arrest progression of ectasia in patients with keratoconus.

To compare the effect, failure rate and the risks of corneal cross-linking (CXL) in keratoconus patients aged ≥35 years to patients <35 years. The aim of this study was to investigate the effect ...

In the end, I do think that the number of corneal transplants for keratoconus is going down in an area of the world where CXL has been available since 2007. It may well be because of CXL, but ...

To compare the long-term outcomes of accelerated corneal collagen crosslinking (CXL) to conventional CXL for progressive keratoconus. Comparative clinical study of consecutive progressive ...

A study carried out at the Royal Liverpool University Hospital evaluated keratoconus progression in 46 eyes of 34 patients who were delayed for CXL treatment by approximately 3 months due to the ...

CXL of the cornea using UVA and riboflavin has been found to be effective in halting the progression of keratoconus. [24] There also seems to be a negative association between diabetes mellitus ...

SHERBORN, Mass.--(BUSINESS WIRE)--CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking ...

The original, traditional Epithelium Off developed in the 1990s, corneal cross-linking (CXL) treatment aims to halt the progression of keratoconus by creating new collagen bonds in the cornea ...

The idea is that EpiSmart can treat keratoconus without disturbing the epithelium tissue, which Epion hopes will allow “for a rapid return to normal activities,” it said in a July 6 press release.

CXL Ophthalmics, Inc., a leading innovator in corneal disease treatments, is pleased to announce its new name as Epion Therapeutics, Inc. The new name ...